THDBH130 in Hyperuricemia With or Without Gout – Phase 2

Phase 2, randomised, double-blind trial of THDBH130 in hyperuricemia and gout (3 arms), sponsored by Nanjing Mingde New Drug Research and Development. Primary endpoints: Incidence and severity of adverse events, serious adverse events, and safety assessment abnormalities and Proportion of patients with serum uric acid ≤ 6 mg/dL at week 4. Started Nov 2022; status: completed.